A series of carcinoid tumours of the breast

Hartgrink, H.H.; Lagaay, M.B.; Spaander, P. J.; Mulder, H.; Breslau, Paul J.

doi:10.1016/s0748-7983(95)95219-5

Cited by 18 publications

(13 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In view of the existing literature, most papers present case reports [4,5,[17][18][19]. In the review by Upalakalin et al [20], the authors report on 59 cases of neuroendocrine tumors in the literature.…”

Section: Discussionmentioning

confidence: 99%

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Richter-Ehrenstein

Arndt

Buckendahl

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Neuroendocrine breast carcinomas are rare but may represent either metastatic or primary lesions. So far, clinical and preoperative histopathological examinations do not distinguish properly between a primary or metastatic breast tumor. Due to any possible consequences following an appropriate treatment, markers which may be helpful for such a distinguishment are needed. We addressed this study in order to evaluate the immunohistochemical expression of GCDFP-15 and mammaglobin in a subset of pure neuroendocrine breast carcinomas (n = 9) and compared the expression profile with a cohort of non-mammary neuroendocrine tumors (n = 99). We observed in our study that solid neuroendocrine breast carcinomas are characterized by the expression of estrogen and progesterone receptors as well as GCDFP-15 and/or mammaglobin. GCDFP-15 was expressed in 6 out of 9 cases, mammaglobin was positive in 4 out of 9 tumors. In contrast, neuroendocrine tumors of the non-mammary cohort expressed neither GCDFP-15 nor mammaglobin. We conclude that mammaglobin and GCDFP-15 as markers of epithelial breast origin may work as a new and reliable diagnostic tool to distinguish primary endocrine tumors of the breast from a metastatic neuroendocrine disease. This is of utmost importance, especially for surgical management.

show abstract

Section: Discussionmentioning

confidence: 99%

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Richter-Ehrenstein

Arndt

Buckendahl

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…There is no standard treatment protocol and a large variety of chemotherapy protocols have been employed in treating this disease. Local treatment is ranging from breast‐conserving surgery or mastectomy followed by axillary lymph node dissection . Systemic therapy principles have been derived from small retrospective case reviews of primary NEC and extrapolated from studies of nonbreast NEC, since the clinical behavior and histology are similar.…”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Carcinoma of the Breast Metastatic to the Bones, Which Chemotherapy?

et al. 2017

View full text Add to dashboard Cite

The primary neuroendocrine carcinoma (NEC) of the breast is defined as immunohistochemical expression of neuroendocrine markers (chromogranin and synoptophysin) in more than 50% of the neoplastic cells according to World Health Organization (WHO) classification of tumors in 2003 (Tumours of the Breast and Female Genital Organs, 2003, Lyon: IARC Press). It accounts for less than 5% of all cancers arising from the breast (Tumours of the Breast and Female Genital Organs, 2003, Lyon, France: IARC Press). However, based on the study conducted by Wang et al., the primary NEC of breast comprises less than 0.1% of all mammary carcinomas (Frankf Z Pathol, 73, 1963, 24). Because of the rarity of the disease and absence of the prospective trials, there is no standard treatment for primary NEC of the breast. Herein, we report the case of a middle age woman with primary NEC with bone metastasis.

show abstract

“…Early diagnosis of the disease, which reduces treatment only to surgical excision of the tumour, is also emphasised. The rarity of cases results in a lack of a unified treatment doctrine for patients with NET [8,[19][20][21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine Carcinoma of the Breast – Preliminary Analysis of Treatment Results of 30 Patients

2017

ARC Journal of Gynecology and Obstetrics

View full text Add to dashboard Cite

A series of carcinoid tumours of the breast

Cited by 18 publications

References 15 publications

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Primary Neuroendocrine Carcinoma of the Breast Metastatic to the Bones, Which Chemotherapy?

Neuroendocrine Carcinoma of the Breast – Preliminary Analysis of Treatment Results of 30 Patients

Contact Info

Product

Resources

About